An Open-label Trial to Evaluate the Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and an N1303K Mutation Who are Not Currently Eligible for an FDA-Approved Modulator

Grant

Total Award Amount

  • 554661.00
  • Direct Costs

  • 495767.00
  • Sponsor Award Id

  • 002536121
  • Contributor

  • Carmel McNicholas-Bevensee   Investigator  
  • George Solomon   Principal Investigator